A luminescence-based assay for monitoring changes in alpha-synuclein aggregation in living cells.
RSC ADVANCES(2020)
摘要
Parkinson's disease is characterized by the accumulation of protein aggregates in the brain, termed Lewy bodies. Lewy bodies are predominantly composed of alpha-synuclein and mutations that increase the aggregation potential of alpha-synuclein have been associated with early on-set disease. Assays capable of reporting on the solubility of alpha-synuclein in living cells could provide a means to interrogate the influence of mutations on aggregation as well as identify small molecules capable of modulating the aggregation of alpha-synuclein. Herein, we repurpose our previously reported self-assembling NanoLuc luciferase fragments to engineer a platform for detecting alpha-synuclein solubility in living cells. This new assay is capable of reporting on changes in alpha-synuclein solubility caused by disease-relevant mutations as well as inhibitors of aggregation. In the long term, this new assay platform provides a means to investigate the influence of mutations on alpha-synuclein solubility as well as identify potential tool compounds capable of modulating alpha-synuclein aggregation.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要